Nipocalimab Plus Standard Care Improves Daily Living and Quantitative MG Scores in gMG Patients Compared to Placebo.

Patients with generalized myasthenia gravis (gMG) experienced sustained improvements in their daily living activities and quantitative myasthenia gravis scores when treated with nipocalimab in addition to the standard of care, in comparison to those receiving a placebo with the standard of care. Specifically, the clinical trial results showed that individuals receiving nipocalimab alongside standard treatment maintained a noticeable and statistically significant enhancement in their ability to perform daily tasks, as well as improvements in their overall quantitative MG scores, as opposed to the group that received a placebo alongside standard treatment. The reported data reflects observed differences between the treatment groups.

Newsflash | Powered by GeneOnline AI
Date: April 11, 2025

Author

Mark Chiang